Robert Chess Sells 5,000 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the sale, the director now directly owns 16,641 shares in the company, valued at approximately $832,050. This represents a 23.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The shares were sold at an average price of $51.85, for a total transaction of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The stock was sold at an average price of $47.26, for a total value of $170,136.00.

Twist Bioscience Stock Down 3.4 %

TWST stock opened at $43.60 on Friday. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company’s 50-day simple moving average is $46.40 and its 200-day simple moving average is $46.41. The firm has a market cap of $2.59 billion, a P/E ratio of -12.11 and a beta of 1.85.

Institutional Trading of Twist Bioscience

Several institutional investors have recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $34,000. Signaturefd LLC raised its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience during the second quarter valued at $61,000. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the third quarter valued at about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TWST shares. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. TD Cowen restated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Evercore ISI upped their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Wolfe Research started coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Finally, Robert W. Baird upped their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.